HDAC6 and neoplasm: Until recently, most research on HDAC PROTACs was focused on hematological malignancies that are more sensitive to HDAC6 degraders regarding degradation of HDAC6 [253] although some encouraging results were observed in tumor cell lines derived from solid tumors [254].